X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.fiercebiotech.com/biotech/ironwood-spies-new-frontier-1b-drug-exploratory-rare-disease-trial
https://www.prnewswire.com/news-releases/karyopharm-shares-data-at-ash-2023-showing-strong-svr-and-tss-durability-observed-from-phase-1-study-of-selinexor-60mg-and-ruxolitinib-in-jak-inhibitor-jaki-naive-myelofibrosis-patients-with-no-svr-or-tss-progressions-observed--302010754.html
https://www.fiercepharma.com/pharma/competitor-rollouts-and-patent-cliff-incyte-banks-jakafi-resilience-new-disease-and
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-ruxolitinib-phosphate-cream-18329.pdf
https://www.reuters.com/business/healthcare-pharmaceuticals/incyte-skin-disease-drug-children-meets-main-goal-late-stage-study-2023-07-11/
https://www.onclive.com/view/navtemadlin-with-ruxolitinib-leads-to-svr-benefit-in-tp53-wild-type-myelofibrosis
https://www.prnewswire.com/news-releases/karyopharm-initiates-pivotal-phase-3-study-of-xpo1-inhibitor-selinexor-and-ruxolitinib-in-jak-inhibitor-jaki-naive-myelofibrosis-301864950.html
https://www.ema.europa.eu/en/documents/overview/opzelura-epar-medicine-overview_en.pdf
https://www.onclive.com/view/zilurgisertib-with-or-without-ruxolitinib-shows-early-tolerability-activity-in-anemic-myelofibrosis
https://www.clinicaltrialsarena.com/news/blood-cancer-trial-ruxolitinib/
https://www.pharmacompass.com/pdf/news/incyte-biosciences-opzelura-receives-approral-in-europe-69231.pdf
https://www.prnewswire.com/news-releases/karyopharm-announces-presentation-of-updated-phase-1-selinexor-data-in-patients-with-treatment-naive-myelofibrosis-at-aacr-2023-301800719.html
https://endpts.com/incyte-hit-by-crl-on-extended-release-jak-tablets-muddying-plans-for-jakafi-franchise-expansion/
https://endpts.com/incyte-stops-phiii-trial-for-pi3k-inhibitor-after-primary-endpoint-failure/
https://www.reuters.com/business/healthcare-pharmaceuticals/incyte-discontinue-late-stage-trial-bone-marrow-cancer-drug-combination-2023-03-03/
https://www.clinicaltrialsarena.com/news/imago-myelofibrosis-treatment-trial/
https://www.globenewswire.com/news-release/2022/12/20/2577487/0/en/Imago-BioSciences-Announces-First-Participant-Dosed-in-Investigator-Sponsored-Phase-2-Study-of-Bomedemstat-in-Combination-with-Ruxolitinib-in-Myelofibrosis.html
https://www.globenewswire.com//news-release/2022/12/12/2572039/0/en/Imago-BioSciences-Presents-Positive-Data-from-Ongoing-Phase-2-Study-of-Bomedemstat-in-Advanced-Myelofibrosis-at-ASH-2022.html
https://www.prnewswire.com/news-releases/abbvie-presents-data-at-the-64th-american-society-of-hematology-ash-annual-meeting-for-investigational-navitoclax-in-combination-with-ruxolitinib-for-jak-inhibitor-naive-myelofibrosis-patients-301699766.html
https://www.globenewswire.com/news-release/2022/12/10/2571387/0/en/AltruBio-Presents-New-Positive-Data-from-its-Completed-Phase-1b-Study-Evaluating-ALTB-168-in-Patients-with-Steroid-Refractory-or-Treatment-Refractory-Acute-Graft-Versus-Host-Diseas.html
https://www.fiercepharma.com/pharma/leo-pharma-shows-promise-its-jak-inhibitor-cream-chronic-hand-eczema
https://www.fiercepharma.com/pharma/discounts-incytes-eczema-cream-opzelura-improve-year-end-goal-still-way-go
https://www.fiercebiotech.com/biotech/fda-declines-free-maats-microbiome-drug-clinical-hold-after-year
https://www.fiercepharma.com/marketing/incyte-plots-ambitious-and-wide-ranging-marketing-campaign-opzeluras-new-vitiligo-licence
https://www.prnewswire.com/news-releases/global-cord-blood-corporation-announced-cellenkos-receives-fda-clearance-of-ind-application-for-ck0804-as-add-on-therapy-to-ruxolitinib-for-the-treatment-of-myelofibrosis-301569662.html
https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-jakavi-be-first-post-steroid-treatment-acute-and-chronic-graft-versus-host-disease
https://www.fiercepharma.com/manufacturing/consumer-complaint-reveals-problem-incytes-eczema-cream-opzelura-again
https://endpts.com/fda-orders-incyte-to-hold-up-yet-again-in-the-hunt-for-blockbuster-franchise/
https://www.fiercepharma.com/pharma/despite-strong-efficacy-dermatologist-survey-indicates-incyte-s-opzelura-may-have-difficulty
https://www.fiercepharma.com/pharma/incyte-combats-early-payer-hurdle-for-eczema-cream-opzelura-but-dermatologists-fully-board
Market Place
Share 
